PCRI is committed to giving you the most up-to-date information and connecting you with professional support to fight prostate cancer. The PCRI process of education leading to empowered decision-making rests on the foundation of the contemporary “Patient-Centric Healthcare” (1). One critical aspect of this is simply called “Self-Care” (2).
Viewing entries tagged
prostate cancer patient
Radium-223 (Alpharadin) A Novel Targeted Alpha-Emitter for Bone-Metastatic Castrate-Resistant Prostate Cancer
Radium-223 (or Alpharadin) is a new targeted alpha-emitting agent which has shown a prolongation of survival in castrate-resistant prostate cancer patients with bone-metastatic disease (5).
The stress of a diagnosis of cancer can throw patients into an “altered state” in which they are particularly vulnerable to suggestion—good or bad. And because most of us, as children, are taught to believe in the infallibility of doctors, the manner in which a doctor delivers a life-threatening diagnosis has a profound effect, and actually has the power to influence the course of the disease.